Advertisement
Advertise here Publish your press releases here Sponsor BioPortfolio
Follow us on Twitter Sign up for daily news and research emails Contributors wanted

Search Results for "Xarelto Vs Pradaxa"

05:47 EDT 21st April 2014 | BioPortfolio

Matching Channels

Rivaroxaban

Rivaroxaban is the most broadly indicated novel oral anticoagulant and is marketed under the brand name Xarelto®. To date, Xarelto has been approved for use in the following indications across t...

Matching News

NICE issues draft AF guidelines

The U.K.'s NICE issued draft guidelines on managing atrial fibrillation (AF) that recommend the use of four drugs. To prevent stroke and systemic embolism in adults with non-valvular AF with one or mo...

Johnson & Johnson Vs. Pfizer, Bristol In The Race Of Anticoagulants

By Peter Geschek:Among the three leading new anticoagulants, Xarelto and Pradaxa are charging ahead in sales, while Eliquis is merely crawling.Johnson & Johnson (JNJ) and Bayer's (OTCPK:BAYRY) dru...

Can Eliquis Play Catch Up? New Indication Should Help

Pfizer and Bristol-Myers Squibb’s Eliquis is now approved for a new use after orthopedic surgery. In competition with the broadly labeled Xarelto and Boehringer’s Pradaxa, Eliquis had a slower tha...

Xarelto in long-term clot prevention study

Bayer has launched a trial of its anticoagulant Xarelto in long-term, secondary prevention of blood clots.The EINSTEIN CHOICE study will investigate Xarelto (rivaroxaban) 10 mg and 20 mg once daily fo...

Physician Views: Can Bayer deliver on its Xarelto bullishness?

Recently added to the BioPortfolio report store, Physician Views: Can Bayer deliver on its Xarelto bullishness? is a new report from Firstword published on 2014-03-09. This report is available from...

Pradaxa gains new US blood clot approval

Boehringer Ingelheim's Pradaxa has gained FDA approval for treatment of deep venous thrombosis (DVT) and pulmonary embolism (PE).The US approval is good news for Boehringer, and comes despite ongoing...

New data at American Society of Hematology (ASH) Annuaul Meeting will offer important insights into safe and efficacious use of XARELTO®

XARELTO® is the most prescribed novel oral anticoagulant in the U.S. Market today...

New long-term treatment data confirms consistent benefit and safety profile of Pradaxa® beyond 6 years

• Pradaxa® (dabigatran etexilate) is the only novel oral anticoagulant with more than 6 years of long-term data supporting its beneficial role for stroke prevention in atrial fibrillation1• The e...

Matching PubMed Articles

Perioperative management and therapy of bleeding complications.

The new oral anticoagulants directly inhibit either thrombin (Dabigatran, Pradaxa®,) or activated Factor X (rivaroxaban, Xarelto®, and apixaban, Eliquis®) and have been approved for thromboprophyla...

Adherence and outcomes of patients prescribed dabigatran (Pradaxa) in routine clinical practice.

To explore and detail clinical experiences of dabigatran, a novel anticoagulant, after it became available in New Zealand in July 2011.

{blacktriangledown} Apixaban and {blacktriangledown} rivaroxaban for stroke prevention in AF.

In October 2011, DTB reviewed the use of dabigatran, the first new oral anticoagulant licensed for the prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillatio...

Rivaroxaban: A Review of Its Use in the Treatment of Deep Vein Thrombosis or Pulmonary Embolism and the Prevention of Recurrent Venous Thromboembolism.

Rivaroxaban (Xarelto(®)), an oral direct factor Xa inhibitor, is approved for the initial treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), as well as the prevention of recurrent D...

Search Whole site using Google

Loading
Search BioPortfolio:
Advertisement
Advertisement
Advertisement Advertisement